ReviewFrontiers in cellular and infection microbiology2019
Thalidomide and Phosphodiesterase 4 Inhibitors as Host Directed Therapeutics for Tuberculous Meningitis: Insights From the Rabbit Model.
Review in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Ischaemia in tuberculous meningitis: update on pathophysiology, clinical predictors and management.Current opinion in infectious diseases · 2026Review
- The Impact of Animal Models and Strain Standardization on the Evaluation of Tuberculosis Vaccine Efficacy.Vaccines · 2025Review
- Host Immune Response toJournal of inflammation research · 2025Review
- Advances in the Treatment and Clinical Management Strategies of Tuberculous Meningitis.International journal of general medicine · 2025Review
- The Role of Oxidative Stress in TB Meningitis and Therapeutic Options.Diseases (Basel, Switzerland) · 2024Review
- Systemic and cerebrospinal fluid biomarkers for tuberculous meningitis identification and treatment monitoring.Microbiology spectrum · 2024Article
- Tuberculous meningitis diagnosis and treatment: classic approaches and high-throughput pathways.Frontiers in immunology · 2024Review
- Role of Oxidative Stress in Tuberculosis Meningitis Infection in Diabetics.Biomedicines · 2023Review
- Tuberculosis meningitis coexisting with HIV Infection: a comprehensive review.Frontiers in tuberculosis · 2023Review
- A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection.Frontiers in immunology · 2023Article
- Performance Evaluation of a Preclinical SPECT Scanner with a Collimator Designed for Medium-Sized Animals.Molecular imaging · 2022Article
- The Dark Side of the COVID-19 Treatments onMediterranean journal of hematology and infectious diseases · 2022Review
- Tuberculous Granuloma: Emerging Insights From Proteomics and Metabolomics.Frontiers in neurology · 2022Review
- The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review.Antibiotics (Basel, Switzerland) · 2021Review
- One Size Fits All? Not inFrontiers in cellular and infection microbiology · 2021Review
- Therapeutic advances in neuroinfectious diseases.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculous meningitis (TBM) is the most devastating form of extrapulmonary
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.